CClinicalTrials.gg
Sign In
CompletedNCT03393767Updated Jan 8, 2018

Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

A Phase 4 interventional study of Ranibizumab in Choroidal Neovascularization and Age Related Macular Degeneration, sponsored by Vista Klinik. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-01-08.

Sponsored by Vista Klinik · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at baseline as assessed by weekly high resolution optical coherence tomography (OCT). Detection of persisting or new signs of CNV activity at OCT triggers further ranibizumab treatments considering that any ranibizumab injections can maximally be applied as often as 2-weekly.

Read the detailed description

This is a prospective, 1-arm, monocenter study designed to evaluate the time course of early re-activation of CNV assessed by High Resolution OCT. An OCT-guided high frequency (up to 2-weekly) intravitreal ranibizumab treatment in CNV due to AMD may prevent further growth and early re-growth of CNV as evaluated by OCT at a weekly basis.

Consenting, enrolled patients will receive one 0.5 mg ranibizumab intravitreal injection at baseline (month 0). Afterwards all patients will undergo a weekly OCT assessment. Further treatments, which can maximally be applied as often as 2-weekly, are triggered by persisting or new signs of CNV activity at OCT as defined by intraretinal cysts or subretinal fluid. For this study, a month is defined as 28 days, a 2-week period as 14 days. During the 12-month study period, a maximum of 24 ranibizumab injections may be administered.

An interim analysis will not be performed. The study will be conducted in compliance with the protocol, GCP and the applicable regulatory requirement(s).

02

Conditions studied

  • Choroidal Neovascularization
  • Age Related Macular Degeneration

Keywords

  • CNV
  • AMD
  • ranibizumab
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female patients ≥ 50 years of age.
  • Patients with active primary subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component.
  • Evidence that CNV extends under the geometric center of the foveal avascular zone.
  • Total CNV area encompassed within the lesion must be ≥ 50% of total lesion area.
  • The total lesion area ≤ 12 disc areas for minimally classic or occult with no classic component and ≤ 9 disc areas (5400µm) in greatest linear dimension with predominantly classic lesions.
  • Patients who have a BCVA of 20/32 to 20/320 (letter score of 78 to 25 letters) in the study eye using ETDRS charts.
  • Willing and able to give written informed consent according to legal requirements, and who have signed the consent form prior to initiation of any study procedure.
  • Willing and able to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either ≥ 50% of the total lesion area or ≥ 1 disc area in size.
  • Structural damage to the center of the macula (beside CNV) in the study eye.
  • Presence of a retinal pigment epithelial tear involving the macula in the study eye.
  • Patients with angioid streaks or precursors of CNV in either eye due to other causes.
  • Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the 12-month study period.
  • Vitreous hemorrhage, history of rhegmatogenous retinal detachment or macular hole.
  • Active intraocular inflammation (grade trace or above) in the study eye.
  • Any active infection involving ocular adnexa.
  • History of uncontrolled glaucoma in the study eye.
  • Aphakia with absence of the posterior capsule in the study eye.
  • Any prior treatment in the study eye with verteporfin, subfoveal focal laser photo-coagulation, vitrectomy, transpupillary thermotherapy, intravitreally applied drugs.
  • History of submacular surgery or other surgical intervention for AMD in the study eye.
  • Extracapsular extraction of cataract within 3 months preceding Baseline.
  • Previous violation of posterior capsule in the study eye (unless YAG capsulotomy).
  • History of Stroke.
  • Pregnant or nursing (lactating) women.
  • History of hypersensitivity or allergy to fluorescein.
  • Inability to obtain OCT/photographs/fluorescein angiograms of sufficient quality.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    prospective 1- Arm

    OCT-guided high frequency intravitreal ranibizumab 0.5mg

    Drug: Ranibizumab

Interventions

  • DrugRanibizumab

    Intravitreal injection

    Also known as: Lucentis

05

What researchers measure

Primary outcomes

  1. Change in CNV activity (any fluid) as assessed by High Resolution OCT

    The primary objective is to evaluate the time course of early re-activation of CNV assessed by High Resolution OCT.

    Time frame: 12 month OCT Assessment

Secondary outcomes

  1. To evaluate the correlation between activation of CNV evaluated by OCT (any fluid) and changes of BCVA.

    ► To evaluate the correlation between activation of CNV evaluated by OCT (any fluid) and changes of BCVA.

    Time frame: 12 month

  2. To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on BCVA changes at month 12.

    To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on BCVA changes at month 12.

    Time frame: 12 months

  3. To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on the total number of injections needed within the 12 months observation period.

    To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on the total number of injections needed within the 12 months observation period.

    Time frame: 12 months

  4. To evaluate the safety and tolerability of up to 2-weekly dosing of ranibizumab by determining the rates of adverse events and serious adverse events at month 12.

    To evaluate the safety and tolerability of up to 2-weekly dosing of ranibizumab by determining the rates of adverse events and serious adverse events at month 12.

    Time frame: 12 months

06

Study locations

1 site
  • Vista Klinik
    Binningen, 4102, Switzerland
07

Registry details

Key details

Study ID
NCT03393767
Lead sponsor
Vista Klinik
Responsible party
Dr. med. Katja Hatz (Prof. Christian Pruente, Vista Klinik) — Principal investigator
First posted
Jan 8, 2018
Start date
Dec 2010
Primary completion
Oct 2016
Completion
Dec 2016
Last update
Jan 8, 2018

Study contacts

Christian Pruente, MD
principal investigator · Vista Klinik

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Macular Degeneration→

Other studies from this sponsor

Vista Klinik

Start the discussion